Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis

Other illness

• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies

Other

• Participant does not have reliable and consistent access to communication (e.g., telephone/mobile phone)
• Participant resides in a location that, in the investigator's opinion, does not allow for timely access to an emergency medical facility
• Pregnant or breastfeeding, or intending to become pregnant during the study or within the time frame in which contraception is required
• Sensitivity or intolerance to any ingredient (including excipients) of ocrelizumab
• Sensitivity or intolerance to acrylic

• Age 18-65 years at the time of signing Informed Consent Form
• Willing and able to receive injections using the OBDS, as either a self-injection or administered by a lay caregiver For participants who are willing to complete self-injection: deemed by the healthcare provider to be able to do the injection based on motor and cognitive function
• For female participants of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during the treatment period and for 6 months after the final dose of ocrelizumab
• For female participants without childbearing potential: Female participants may be enrolled if postmenopausal
• Currently being treated with ocrelizumab: At least one prior dose of ocrelizumab 600 mg IV or 920 mg SC Note: The first dose of ocrelizumab in this study will be administered approximately 6 months (± 1 month) after a previous (pre-study) ocrelizumab dose (and may not be administered earlier than 5 months after the last pre-study ocrelizumab dose)
• Diagnosis of MS according to the revised McDonald 2024 criteria (Montalban et al. 2025) or the most current published revision of the McDonald criteria at the time of study start